Investor Presentaiton
Oncology
Opdivo
Opdualag TIGIT Bispecific DGK Inhibitor
AR LDD
Adjuvant Melanoma: High conviction indication with
potential to benefit patients before disease spreads
Clear evidence of neo-adjuvant activity with relatlimab and nivolumab
complements proven benefit in metastatic setting
PCR, n/N (%)
Nivo + Rela²
Nivo 1
3/12 (25)
Nivo+Rela²
17/30 (57)
Probability of Recurrence-Free Survival
0.0
0.2
0.4
0.6
0.8
1.0
PCR
non PCR
T
T
-5
p = 0.10
T
T
T
10
15
20 25
30
35
ФГ
Months After Surgery
PCR 17
17
15
13
10
5
1
0
non PCR 12
11
11
8
7
3
0
0
Combination relatlimab and
nivolumab yields a high pCR
rate and durable clinical
benefit in resectable
melanoma patients
Favorable safety profile
Opdualag: Potential therapy option for ~21K adjuvant patients vs ~13K 1L metastatic patients in the U.S.³
RELATIVITY-098 Phase 3 ongoing: Data expected in 2026
1. Amaria, et al. Nat Med 2018; 24: 1649-54; 2. Amaria, et al. Nat Med 2022; 611: 155-60; 3. Decision Resources Group, BMS Internal Analysis
Ill Bristol Myers Squibb™
Not for Product Promotional Use
99View entire presentation